Compare NUVL & HUBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | HUBS |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | 228 | 9021 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 10.2B |
| IPO Year | 2021 | 2014 |
| Metric | NUVL | HUBS |
|---|---|---|
| Price | $110.87 | $221.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 32 |
| Target Price | $134.75 | ★ $435.19 |
| AVG Volume (30 Days) | 454.3K | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 855.56 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $375,612,000.00 |
| Revenue This Year | N/A | $20.46 |
| Revenue Next Year | $1,239.49 | $16.01 |
| P/E Ratio | ★ N/A | $319.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.14 | $173.25 |
| 52 Week High | $113.02 | $611.00 |
| Indicator | NUVL | HUBS |
|---|---|---|
| Relative Strength Index (RSI) | 64.36 | 54.90 |
| Support Level | $97.99 | $209.40 |
| Resistance Level | $112.61 | $225.58 |
| Average True Range (ATR) | 3.54 | 12.85 |
| MACD | 0.84 | 2.20 |
| Stochastic Oscillator | 92.70 | 91.76 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.